Dr. Ai on the Efficacy of Brentuximab Vedotin in Patients With Advanced Cutaneous T-Cell Lymphoma
5 Visningar
• 08/09/23
0
0
Bädda in
administrator
Prenumeranter
Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, discusses the scenarios in which she has seen the most benefit from brentuximab vedotin (Adcetris) in patients with advanced stage cutaneous T-cell lymphoma (CTCL).
Visa mer
Facebook-kommentarer
SORT BY-
Toppkommentarer
-
Senaste kommentarerna